Literature DB >> 16184011

Enhanced analgesic effect of morphine-nimodipine combination after intraspinal administration as compared to systemic administration in mice.

Dilip Verma1, Subrata Basu Ray, Ishan Patro, Shashi Wadhwa.   

Abstract

Calcium plays an important role in the pathophysiology of pain. A number of studies have investigated the effect of L-type calcium channel blockers on the analgesic response of morphine. However, the results are conflicting. In the present study, the antinociceptive effect of morphine (2.5 microg) and nimodipine (1 microg) co-administered intraspinally in mice was observed using the tail flick test. It was compared to the analgesic effect of these drugs (morphine - 250 microg subcutaneously; nimodipine - 100 microg intraperitoneally) after systemic administration. Nimodipine is highly lipophilic and readily crosses the blood brain barrier. Addition of nimodipine to morphine potentiated the analgesic response of the latter when administered through the intraspinal route but not when administered through systemic route. It may be due to direct inhibitory effect of morphine and nimodipine on neurons of superficial laminae of the spinal cord after binding to mu -opioid receptors and L-type calcium channels respectively.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16184011     DOI: 10.1007/bf02703723

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  31 in total

Review 1.  Structure and regulation of voltage-gated Ca2+ channels.

Authors:  W A Catterall
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

2.  The enigma of morphine tolerance: recent insights.

Authors:  S B Ray; S Wadhwa
Journal:  J Biosci       Date:  2001-12       Impact factor: 1.826

Review 3.  Presynaptic Ca2+ channels: a functional patchwork.

Authors:  Christopher A Reid; John M Bekkers; John D Clements
Journal:  Trends Neurosci       Date:  2003-12       Impact factor: 13.837

4.  Effects of N- and L-type calcium channel antagonists on the responses of nociceptive spinal cord neurons to mechanical stimulation of the normal and the inflamed knee joint.

Authors:  V Neugebauer; H Vanegas; J Nebe; P Rümenapp; H G Schaible
Journal:  J Neurophysiol       Date:  1996-12       Impact factor: 2.714

5.  Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats.

Authors:  Y X Wang; D Gao; M Pettus; C Phillips; S S Bowersox
Journal:  Pain       Date:  2000-02       Impact factor: 6.961

6.  The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices.

Authors:  Maree T Smith; Peter J Cabot; Fraser B Ross; Alan D Robertson; Richard J Lewis
Journal:  Pain       Date:  2002-03       Impact factor: 6.961

7.  Calcium channel modulation by dihydropyridines modifies sufentanil-induced antinociception in acute and tolerant conditions.

Authors:  M Dierssen; J Flórez; M A Hurlé
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-11       Impact factor: 3.000

8.  Antinociceptive effects of intrathecal L-type calcium channel blockers on visceral and somatic stimuli in the rat.

Authors:  K Hara; Y Saito; Y Kirihara; S Sakura; Y Kosaka
Journal:  Anesth Analg       Date:  1998-08       Impact factor: 5.108

9.  Effect of intrathecal nimodipine on spinal cord blood flow and evoked potentials in the normal or injured cord.

Authors:  H Imamura; C H Tator
Journal:  Spinal Cord       Date:  1998-07       Impact factor: 2.772

10.  Calcium channel antagonists increase morphine-induced analgesia and antagonize morphine tolerance.

Authors:  E Contreras; L Tamayo; M Amigo
Journal:  Eur J Pharmacol       Date:  1988-04-13       Impact factor: 4.432

View more
  1 in total

1.  Analgesia Synergism of Essential Oil from Pericarp of Zanthoxylum schinifolium and Verapamil.

Authors:  Gao Wu; Hanbin Wu
Journal:  Evid Based Complement Alternat Med       Date:  2014-07-08       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.